UA80809C2 - Process for preparation of protective antigen protein of anthracis with e.coli - Google Patents

Process for preparation of protective antigen protein of anthracis with e.coli Download PDF

Info

Publication number: UA80809C2
Authority: UA; Ukraine
Prior art keywords: cells; medium; protective antigen; protein; recombinant
Prior art date: 2001-07-12

Application number

UA20040503327A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-05

Filing date

2001-07-12

Publication date

2007-11-12

2001-07-12 Application filed filed Critical

2007-11-12 Publication of UA80809C2 publication Critical patent/UA80809C2/uk

Links

238000000034 method Methods 0.000 title claims abstract description 34
101710194807 Protective antigen Proteins 0.000 title claims abstract description 22
241000588724 Escherichia coli Species 0.000 title abstract description 5
238000002360 preparation method Methods 0.000 title abstract description 5
230000008569 process Effects 0.000 title abstract description 4
241000193738 Bacillus anthracis Species 0.000 claims abstract description 8
108091007433 antigens Proteins 0.000 claims abstract description 3
102000036639 antigens Human genes 0.000 claims abstract description 3
210000004027 cell Anatomy 0.000 claims description 69
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 45
108090000623 proteins and genes Proteins 0.000 claims description 34
102000004169 proteins and genes Human genes 0.000 claims description 30
235000010469 Glycine max Nutrition 0.000 claims description 18
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 18
238000004113 cell culture Methods 0.000 claims description 16
239000013612 plasmid Substances 0.000 claims description 16
244000068988 Glycine max Species 0.000 claims description 15
230000014509 gene expression Effects 0.000 claims description 15
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
239000001301 oxygen Substances 0.000 claims description 13
229910052760 oxygen Inorganic materials 0.000 claims description 13
238000000855 fermentation Methods 0.000 claims description 12
230000004151 fermentation Effects 0.000 claims description 12
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
239000004202 carbamide Substances 0.000 claims description 10
239000008103 glucose Substances 0.000 claims description 10
239000000654 additive Substances 0.000 claims description 9
238000005119 centrifugation Methods 0.000 claims description 8
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 7
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
230000003287 optical effect Effects 0.000 claims description 7
239000006228 supernatant Substances 0.000 claims description 7
150000001720 carbohydrates Chemical class 0.000 claims description 6
235000014633 carbohydrates Nutrition 0.000 claims description 6
150000007524 organic acids Chemical class 0.000 claims description 6
229920005862 polyol Polymers 0.000 claims description 6
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 5
239000008101 lactose Substances 0.000 claims description 5
239000001630 malic acid Substances 0.000 claims description 5
235000011090 malic acid Nutrition 0.000 claims description 5
150000003077 polyols Chemical class 0.000 claims description 5
230000001681 protective effect Effects 0.000 claims description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
229930091371 Fructose Natural products 0.000 claims description 4
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
239000005715 Fructose Substances 0.000 claims description 4
230000000996 additive effect Effects 0.000 claims description 4
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
229930182830 galactose Natural products 0.000 claims description 4
238000003756 stirring Methods 0.000 claims description 4
239000013598 vector Substances 0.000 claims description 4
238000001262 western blot Methods 0.000 claims description 3
239000000427 antigen Substances 0.000 claims description 2
238000004587 chromatography analysis Methods 0.000 claims description 2
230000009089 cytolysis Effects 0.000 claims description 2
238000010828 elution Methods 0.000 claims description 2
235000005985 organic acids Nutrition 0.000 claims description 2
230000007928 solubilization Effects 0.000 claims description 2
238000005063 solubilization Methods 0.000 claims description 2
238000003860 storage Methods 0.000 claims description 2
230000009466 transformation Effects 0.000 claims description 2
230000000890 antigenic effect Effects 0.000 claims 1
238000001962 electrophoresis Methods 0.000 claims 1
210000003000 inclusion body Anatomy 0.000 claims 1
238000012544 monitoring process Methods 0.000 claims 1
229960000856 protein c Drugs 0.000 claims 1
238000000926 separation method Methods 0.000 claims 1
229940065181 bacillus anthracis Drugs 0.000 abstract 1
239000002609 medium Substances 0.000 description 23
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
229910052799 carbon Inorganic materials 0.000 description 18
235000011187 glycerol Nutrition 0.000 description 15
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 12
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 10
235000015097 nutrients Nutrition 0.000 description 10
239000000758 substrate Substances 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 9
230000001965 increasing effect Effects 0.000 description 9
239000000047 product Substances 0.000 description 8
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
239000001963 growth medium Substances 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
238000000746 purification Methods 0.000 description 5
239000000523 sample Substances 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000012010 growth Effects 0.000 description 4
229910000160 potassium phosphate Inorganic materials 0.000 description 4
235000011009 potassium phosphates Nutrition 0.000 description 4
239000013049 sediment Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
229960002235 anthrax antigen Drugs 0.000 description 3
239000002518 antifoaming agent Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000006698 induction Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000034994 death Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000013578 denaturing buffer Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000012535 impurity Substances 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
239000011573 trace mineral Substances 0.000 description 2
235000013619 trace mineral Nutrition 0.000 description 2
238000013519 translation Methods 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
230000035899 viability Effects 0.000 description 2
JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
239000002028 Biomass Substances 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000035472 Zoonoses Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
229940037003 alum Drugs 0.000 description 1
-1 ammonium ions Chemical class 0.000 description 1
229960005447 anthrax vaccines Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000003995 blood forming stem cell Anatomy 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000006860 carbon metabolism Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000012364 cultivation method Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000003936 denaturing gel electrophoresis Methods 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
235000020774 essential nutrients Nutrition 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
230000004907 flux Effects 0.000 description 1
238000005187 foaming Methods 0.000 description 1
235000012041 food component Nutrition 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
239000003966 growth inhibitor Substances 0.000 description 1
230000017525 heat dissipation Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000007726 management method Methods 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
238000002493 microarray Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000015816 nutrient absorption Nutrition 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000009751 slip forming Methods 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1
206010048282 zoonosis Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
Laminated Bodies (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

UA20040503327A 2001-11-05 2001-07-12 Process for preparation of protective antigen protein of anthracis with e.coli UA80809C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN1127DE2001 IN190590B (de)	2001-11-05	2001-11-05
PCT/IN2001/000215 WO2003040179A1 (en)	2001-11-05	2001-12-07	High level constitutive production of anthrax protective antigen

Publications (1)

Publication Number	Publication Date
UA80809C2 true UA80809C2 (en)	2007-11-12

Family

ID=11097131

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040503327A UA80809C2 (en)	2001-11-05	2001-07-12	Process for preparation of protective antigen protein of anthracis with e.coli

Country Status (15)

Country	Link
US (1)	US7329513B2 (de)
EP (1)	EP1442052B1 (de)
JP (1)	JP2005510215A (de)
CN (1)	CN100347189C (de)
AT (1)	ATE484517T1 (de)
BR (1)	BRPI0117173A2 (de)
CA (1)	CA2465679A1 (de)
DE (1)	DE60143276D1 (de)
IL (1)	IL161725A0 (de)
IN (1)	IN190590B (de)
MX (1)	MXPA04004281A (de)
RU (1)	RU2288272C2 (de)
UA (1)	UA80809C2 (de)
WO (1)	WO2003040179A1 (de)
ZA (1)	ZA200403396B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA80809C2 (en) *	2001-11-05	2007-11-12		Process for preparation of protective antigen protein of anthracis with e.coli
WO2005026375A2 (en)	2003-05-22	2005-03-24	Fraunhofer Usa, Inc.	Recombinant carrier molecule for expression, delivery and purification of target polypeptides
AU2003271835A1 (en) *	2003-06-06	2005-01-04	Avecia Limited	Process for the separation of proteins
US20060246079A1 (en) *	2003-11-14	2006-11-02	Morrow Phillip R	Neutralizing human antibodies to anthrax toxin
WO2005081749A2 (en) *	2004-01-23	2005-09-09	Avanir Pharmaceuticals, Inc.	Neutralizing human antibodies to anthraxtoxin
US7355027B2 (en)	2004-06-16	2008-04-08	Dynport Vaccine Company Llc	Bacillus anthracis protective antigen
US8101735B2 (en)	2004-06-16	2012-01-24	Health Protection Agency	Preparation of protective antigen
CN100336908C (zh) *	2004-09-10	2007-09-12	中国人民解放军军事医学科学院微生物流行病研究所	一种制备重组炭疽保护性抗原的方法及其专用表达质粒
JP2009502207A (ja)	2005-08-03	2009-01-29	フラウンホーファーユーエスエー，インコーポレイテッド	イムノグロブリンの産生のための組成物および方法
US8277816B2 (en) *	2006-02-13	2012-10-02	Fraunhofer Usa, Inc.	Bacillus anthracis antigens, vaccine compositions, and related methods
BRPI0707733B1 (pt)	2006-02-13	2019-12-31	Ibio, Inc.	antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
GB0607462D0 (en) *	2006-04-13	2006-05-24	Avecia Ltd	Assay
US7794732B2 (en) *	2006-05-12	2010-09-14	Oklahoma Medical Research Foundation	Anthrax compositions and methods of use and production
US8420607B2 (en) *	2006-06-30	2013-04-16	University Of Georgia Research Foundation, Inc.	Anthrax carbohydrates, synthesis and uses thereof
WO2008115198A2 (en)	2006-06-30	2008-09-25	University Of Georgia Research Foundation, Inc.	Anthrax carbohydrates,synthesis and uses thereof
WO2009009759A2 (en)	2007-07-11	2009-01-15	Fraunhofer Usa, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
WO2009126355A2 (en) *	2008-01-28	2009-10-15	Baxter International, Inc.	Methods of increasing recombinant production of bacillus anthracis protective antigen
US8734803B2 (en)	2008-09-28	2014-05-27	Ibio Inc.	Humanized neuraminidase antibody and methods of use thereof
AU2009299615B2 (en)	2008-10-02	2015-07-16	Pharmathene Inc.	Anthrax vaccine formulation and uses thereof
US20100183675A1 (en) *	2009-01-22	2010-07-22	Allan Watkinson	Stable vaccine compositions and methods of use
US8784819B2 (en)	2009-09-29	2014-07-22	Ibio Inc.	Influenza hemagglutinin antibodies, compositions and related methods
US20120301951A1 (en) *	2010-11-18	2012-11-29	E. I. Du Pont De Nemours And Company	Prevention of contamination of nutrient feed reservoirs & feed lines in bioreactor systems
RU2633504C1 (ru) *	2016-12-27	2017-10-12	Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН)	Штамм E.coli - продуцент полноразмерного протективного антигена Bacillus anthracis в форме вирусоподобных частиц
RU2633508C1 (ru) *	2016-12-27	2017-10-12	Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН)	Штамм E. coli - продуцент изолированного домена 1 протективного антигена Bacillus anthracis в форме вирусоподобных частиц
CN115125224B (zh) *	2022-08-11	2023-07-18	福州大学	一种可规模化生产具有活性的dna聚合酶的方法
CN117093572A (zh) *	2023-08-24	2023-11-21	中国建设银行股份有限公司	数据补录方法、装置、设备、存储介质及产品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5591631A (en) *	1993-02-12	1997-01-07	The United States Of America As Represented By The Department Of Health And Human Services	Anthrax toxin fusion proteins, nucleic acid encoding same
US5677274A (en) *	1993-02-12	1997-10-14	The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services	Anthrax toxin fusion proteins and related methods
US5800821A (en) *	1995-03-10	1998-09-01	New England Medical Center Hospitals, Inc.	Bacterial spores as a heat stable vaccine delivery system
GB9618107D0 (en) *	1996-08-30	1996-10-09	Secr Defence	Vaccine production
US6602712B2 (en) *	1998-04-07	2003-08-05	Wisconsin Alumni Research Foundation	Enterotoxin-deficient bacillus
US20020086032A1 (en) *	1999-02-02	2002-07-04	Mahan Michael J.	Producing antibodies with attenuated bacteria with altered DNA adenine methylase activity
WO2003055977A2 (en) *	2001-10-01	2003-07-10	Regents Of The University Of California	A method for generating overexpression of alleles in genes of unknown function
UA80809C2 (en) *	2001-11-05	2007-11-12		Process for preparation of protective antigen protein of anthracis with e.coli
US7763451B2 (en) *	2001-11-09	2010-07-27	The United States Of America As Represented By The Department Of Health And Human Services	Methods for preparing Bacillus anthracis protective antigen for use in vaccines

2001
- 2001-07-12 UA UA20040503327A patent/UA80809C2/uk unknown
- 2001-11-05 IN IN1127DE2001 patent/IN190590B/en unknown
- 2001-12-07 WO PCT/IN2001/000215 patent/WO2003040179A1/en not_active Ceased
- 2001-12-07 EP EP01274653A patent/EP1442052B1/de not_active Expired - Lifetime
- 2001-12-07 AT AT01274653T patent/ATE484517T1/de not_active IP Right Cessation
- 2001-12-07 DE DE60143276T patent/DE60143276D1/de not_active Expired - Lifetime
- 2001-12-07 US US10/494,680 patent/US7329513B2/en not_active Expired - Fee Related
- 2001-12-07 MX MXPA04004281A patent/MXPA04004281A/es not_active Application Discontinuation
- 2001-12-07 JP JP2003542224A patent/JP2005510215A/ja active Pending
- 2001-12-07 CN CNB018239226A patent/CN100347189C/zh not_active Expired - Fee Related
- 2001-12-07 CA CA002465679A patent/CA2465679A1/en not_active Abandoned
- 2001-12-07 IL IL16172501A patent/IL161725A0/xx unknown
- 2001-12-07 BR BRPI0117173A patent/BRPI0117173A2/pt not_active IP Right Cessation
- 2001-12-07 RU RU2004117085/13A patent/RU2288272C2/ru not_active IP Right Cessation
2004
- 2004-05-05 ZA ZA200403396A patent/ZA200403396B/en unknown

Also Published As

Publication number	Publication date
IL161725A0 (en)	2005-11-20
IN190590B (de)	2003-08-09
EP1442052B1 (de)	2010-10-13
CN1582298A (zh)	2005-02-16
ZA200403396B (en)	2005-08-05
WO2003040179A1 (en)	2003-05-15
CA2465679A1 (en)	2003-05-15
ATE484517T1 (de)	2010-10-15
MXPA04004281A (es)	2005-03-31
DE60143276D1 (de)	2010-11-25
EP1442052A1 (de)	2004-08-04
HK1072610A1 (zh)	2005-09-02
CN100347189C (zh)	2007-11-07
US20050054038A1 (en)	2005-03-10
US7329513B2 (en)	2008-02-12
BRPI0117173A2 (pt)	2018-04-17
RU2004117085A (ru)	2005-03-27
RU2288272C2 (ru)	2006-11-27
JP2005510215A (ja)	2005-04-21

Publication	Publication Date	Title
UA80809C2 (en)	2007-11-12	Process for preparation of protective antigen protein of anthracis with e.coli
Park et al.	1992	Enhanced β‐galactosidase production by high cell‐density culture of recombinant Bacillus subtilis with glucose concentration control
ES2728169T3 (es)	2019-10-22	Procedimiento de cultivo de células de E. coli para alta densidad
Tsuchiya et al.	1996	Effect of homogeneous and inhomogeneous high magnetic fields on the growth of Escherichia coli
Manderson et al.	2006	A recombinant vaccine against hydatidosis: production of the antigen in Escherichia coli
Brown et al.	1985	Continuous production of human leukocyte interferon with Escherichia coli and continuous cell lysis in a two stage chemostat
CN110317803A (zh)	2019-10-11	麦角硫因的纳米生物学制备方法
Szweda et al.	2014	Efficient production of Staphylococcus simulans lysostaphin in a benchtop bioreactor by recombinant Escherichia coli
CN109536427A (zh)	2019-03-29	一种酸胁迫抗性提高的乳酸菌工程菌
Xia et al.	2022	Optimization of process parameters for naringinase production by Aspergillus tubingensis UA13 and pilot scale-up study
CN103937856A (zh)	2014-07-23	一种提高井冈霉素产量的发酵方法
CN104694523A (zh)	2015-06-10	一种精氨酸脱亚胺酶的胞外表达方法及其应用
CN108251375B (zh)	2021-05-07	一种发酵生产重组人白介素-12的方法
Listner et al.	2006	A simple method for the production of plasmid DNA in bioreactors
Kratje et al.	1992	Evaluation of production of recombinant human interleukin‐2 in fluidized bed bioreactor
Chrast et al.	2018	Gram-scale production of recombinant microbial enzymes in shake flasks
CN102776260A (zh)	2012-11-14	一种高效表达重组人凝血八因子的方法
CN114438004B (zh)	2023-08-22	一株pII基因加倍的须糖多孢菌工程菌株及其构建方法与应用
Rhee et al.	1997	Influence of the medium composition and plasmid combination on the growth of recombinant Escherichia coli JM109 and on the production of the fusion protein EcoRI:: SPA
CN114431221B (zh)	2025-11-25	一种抗体生产细胞的冻存制剂、其应用及冻存方法
CN101402954A (zh)	2009-04-08	一种用毕赤嗜甲醇酵母表达重组猪乳铁蛋白n叶的方法
Dedic et al.	1956	Aerobic cultivation of Clostridium tetani in the presence of cobalt
Sode et al.	1988	Continuous production of α-peptide using immobilized recombinant yeast cells: A model for continuous production of foreign peptide by recombinant yeast
Aung et al.	2011	Isolation of mimosine degrading bacteria from rumen juice and mass production by Göttingen bioreactor technology
CN113999834B (zh)	2023-04-07	精氨酸脱亚胺酶生产菌及其构建方法